Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer, Vincent van der Noort, Astrid C P Swinkels, Hedwig M. Blommestein, Cristina Guerrero Páez, L. Mol, Aart Beeker, Karin Beelen, Lisanne C. Hamming, Joan B. Heijns, Aafke H. Honkoop, Paul C. de Jong, Quirine C. van Rossum‐Schornagel, Christa van Schaik-van de Mheen, Jolien Tol, Cathrien S. Tromp-van Driel, Suzan Vrijaldenhoven, A. Elise van Leeuwen‐Stok, Inge R. Konings, Agnes Jager, Paul C. de Jong, Quirine C. van Rossum‐Schornagel, Christa van Schaik-van de Mheen
Topics & Concepts
FulvestrantMedicineHazard ratioInternal medicineOncologyAdverse effectClinical endpointBreast cancerCyclin-dependent kinase 4Confidence intervalRandomizationAromatase inhibitorRandomized controlled trialLetrozoleCancerEstrogen receptorAromataseCyclin-dependent kinase 2Cell cycleAdvanced Breast Cancer TherapiesChronic Lymphocytic Leukemia ResearchCancer-related cognitive impairment studies